The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation - PubMed (original) (raw)
Review
The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation
L Quartara et al. Neuropeptides. 1997 Dec.
Abstract
The tachykinin NK1 receptor is widely expressed in the mammalian central and peripheral nervous system. Powerful pharmacological tools (agonists and antagonists) are now available to elucidate the physiological role of NK1 receptors at these levels, as well as to understand their role in diseases and establish the possible therapeutic usefulness of NK1 receptor antagonists for treatment of human diseases. The structure-activity studies that have led to the development of potent peptide and non-peptide ligands for the tachykinin NK1 receptor are here reviewed. Among the peptide agonists and antagonists, linear and cyclic sequences have been developed. The non peptide antagonists belong to different chemical classes, i.e. steroids, perhydroisoindolones, quinuclidines, piperidines and tryptophane derivatives. The first non peptide antagonists for NK1 receptors have been obtained by random screening of chemical compounds large collections. The resulting leads were optimized with 'classic' structure activity approaches, aiming at identifying 'common' motifs for interaction with the receptor by ligands of different chemical classes. The results derived from the recent application of molecular biology techniques were useful to drive the design of new ligands toward a precise structural definition of ligand-receptor bi-molecular interactions. Studies on mutant receptors have established that the sites of interaction of peptide agonists and non peptide antagonists with the tachykinin NK1 receptor are largely non overlapping. Moreover, data obtained from mutagenesis of the NK1 receptor further indicate that some amino acid residues in the NK1 receptor sequence are critical for determining the binding affinity of some but not all ligands. Therefore, different antagonists discovered from random screening may not possess common points of interaction or common structural and conformational characteristics for their interaction with the tachykinin NK1 receptor. The tachykinin NK1 receptor couples with G-proteins to determine its biological effects in target cells. Several G-proteins both sensitive (Go, Gi) and insensitive (Gq, G11) to pertussis toxin can mediate the action of NK1 receptors. Moreover, several second messanger signalling systems (elevation of intracellular calcium, stimulation of phosphoinositol turnover, arachidonic acid mobilization, cAMP accumulation) have to be activated following NK1 receptor signalling. Also a direct modulation of certain ion channels at membrane level has been proposed. The NK1 receptor undergoes prompt and significant tachyphylaxis upon exposure to the agonist: this has been shown to be linked with receptor internalization which also occurs physiologically when the NK1 receptor is stimulated by endogenous tachykinins.
Similar articles
- The tachykinin NK1 receptor in the brain: pharmacology and putative functions.
Saria A. Saria A. Eur J Pharmacol. 1999 Jun 30;375(1-3):51-60. doi: 10.1016/s0014-2999(99)00259-9. Eur J Pharmacol. 1999. PMID: 10443564 Review. - Typical and atypical NK1 tachykinin receptor characteristics in the rabbit isolated iris sphincter.
Hall JM, Mitchell D, Morton IK. Hall JM, et al. Br J Pharmacol. 1994 Jul;112(3):985-91. doi: 10.1111/j.1476-5381.1994.tb13178.x. Br J Pharmacol. 1994. PMID: 7522864 Free PMC article. - Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice.
Teixeira RM, Santos AR, Ribeiro SJ, Calixto JB, Rae GA, De Lima TC. Teixeira RM, et al. Eur J Pharmacol. 1996 Sep 5;311(1):7-14. doi: 10.1016/0014-2999(96)00390-1. Eur J Pharmacol. 1996. PMID: 8884230 - The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles.
Quartara L, Maggi CA. Quartara L, et al. Neuropeptides. 1998 Feb;32(1):1-49. doi: 10.1016/s0143-4179(98)90015-4. Neuropeptides. 1998. PMID: 9571643 Review.
Cited by
- Decreased vascular permeability response to substance P in airways of genetically hypertensive rats.
Bakhle YS, Brogan JD, Bell C. Bakhle YS, et al. Br J Pharmacol. 1999 Feb;126(4):933-8. doi: 10.1038/sj.bjp.0702377. Br J Pharmacol. 1999. PMID: 10193773 Free PMC article. - Polymorphisms in genes of respiratory control and sudden infant death syndrome.
Läer K, Dörk T, Vennemann M, Rothämel T, Klintschar M. Läer K, et al. Int J Legal Med. 2015 Sep;129(5):977-84. doi: 10.1007/s00414-015-1232-0. Epub 2015 Jul 22. Int J Legal Med. 2015. PMID: 26198620 - Targeting NK-1 Receptors to Prevent and Treat Pancreatic Cancer: a New Therapeutic Approach.
Muñoz M, Coveñas R. Muñoz M, et al. Cancers (Basel). 2015 Jul 6;7(3):1215-32. doi: 10.3390/cancers7030832. Cancers (Basel). 2015. PMID: 26154566 Free PMC article. Review. - Novel Functional Role of NK3R Expression in the Potentiating Effects on Somatolactin α Autoregulation in grass carp pituitary cells.
Hu G, He M, Wong AO. Hu G, et al. Sci Rep. 2016 Oct 27;6:36102. doi: 10.1038/srep36102. Sci Rep. 2016. PMID: 27786296 Free PMC article. - The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer.
Rosso M, Muñoz M, Berger M. Rosso M, et al. ScientificWorldJournal. 2012;2012:381434. doi: 10.1100/2012/381434. Epub 2012 Apr 1. ScientificWorldJournal. 2012. PMID: 22545017 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources